Scienture Holdings, Inc. (SCNX) is a biotechnology company dedicated to revolutionizing the treatment of neurological disorders through its innovative drug development pipeline and experienced research team. With a strong commitment to addressing critical unmet medical needs, the company is positioned to improve patient outcomes while adeptly managing the complexities of regulatory pathways. Scienture's focus on scientific rigor, coupled with strategic partnerships, enhances its growth potential and solidifies its role as a significant player in the global healthcare market. As demand for effective neurological treatments escalates, Scienture is well-equipped to capitalize on emerging opportunities within this expanding sector.
| Revenue (TTM) | 477,680 |
| Gross Profit (TTM) | 384,660 |
| EBITDA | $-15.27M |
| Operating Margin | -6231.00% |
| Return on Equity | -56.60% |
| Return on Assets | -10.80% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $1.65 |
| Price-to-Book | 0.21 |
| Price-to-Sales (TTM) | 28.19 |
| EV/Revenue | 22.17 |
| EV/EBITDA | -1.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 449.10% |
| Shares Outstanding | $40.63M |
| Float | $32.79M |
| % Insiders | 13.31% |
| % Institutions | 3.87% |
Volatility is currently contracting
Commercial availability expected in August as the Company advances the rollout of the highest-dose FDA-approved naloxone hydrochloride nasal spray
Broader pharmacy access, channel expansion, and payer coverage position Arbli ™ for increased prescription volume and revenue growth
Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market
COMMACK, NY / ACCESS Newswire / June 4, 2026 / SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that members of its executive management team will participate in The Small Cap Showcase & WTR Insights, taking place on June 9, 2026, in New York City.
U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually COMMACK, NY, June 02, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that the United States Patent and Trademark Office has granted U.S. Patent No.
COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three months ended March 31, 2026.
U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI ™ as the first FDA-approved ready-to-use oral suspension
